公开(公告)号：US10767171B2

公开(公告)日：2020-09-08

申请号：US16751734

申请日：2020-01-24

申请人： Synthetic Biologics, Inc.

发明人： Michael Kaleko ,  Sheila Connelly

IPC分类号： C12N9/86 ,  A61K38/50 ,  A61K9/00 ,  A61K45/06 ,  A61K31/546 ,  A61K38/00

摘要： This invention relates to, in part, compositions of beta-lactamases and methods of using these enzymes in, for example, gastrointestinal tract (GI tract) disorders such as C. difficile infection (CDI).

公开(公告)号：US10736871B2

公开(公告)日：2020-08-11

申请号：US15560145

申请日：2016-03-31

申请人： Cedars-Sinai Medical Center ,  Synthetic Biologics, Inc.

发明人： Mark Pimentel ,  Vince Wacher

IPC分类号： A61K31/366 ,  A61P1/14 ,  A61K9/00 ,  A61K45/06 ,  A61K9/24 ,  A61K9/16

摘要： The present invention relates to, in part, methods for the treatment of methanogen-associated disorders such as, for example, Irritable Bowel Syndrome (IBS) using at least one anti-methanogenic lovastatin analog or derivative. In addition, modified-release formulations comprising at least one anti-methanogenic lovastatin analog or derivative are provided which release the anti-methanogenic lovastatin analog or derivative in the gastrointestinal tract.

公开(公告)号：US20200222514A1

公开(公告)日：2020-07-16

申请号：US16720999

申请日：2019-12-19

申请人： Synthetic Biologics, Inc.

发明人： Michael KALEKO ,  Sheila CONNELLY

IPC分类号： A61K38/50 ,  A61K38/14 ,  A61K31/00 ,  A61K35/741 ,  A61K31/427 ,  A61K31/43 ,  A61K9/00 ,  C12N9/86

摘要： This invention relates, in part, to various compositions and methods for protecting the gastrointestinal microbiome from antibiotic disruption.

公开(公告)号：US10548955B2

公开(公告)日：2020-02-04

申请号：US15866044

申请日：2018-01-09

申请人： SYNTHETIC BIOLOGICS, INC.

发明人： Michael Kaleko ,  Sheila Connelly

IPC分类号： C12N9/86 ,  A61K38/50 ,  A61K38/14 ,  A61K31/00 ,  A61K35/741 ,  A61K9/00 ,  A61K9/50

摘要： This invention relates, in part, to various compositions and methods for protecting the gastrointestinal microbiome from antibiotic disruption.

公开(公告)号：US20190169590A1

公开(公告)日：2019-06-06

申请号：US16279547

申请日：2019-02-19

申请人： Synthetic Biologics, Inc.

发明人： Pertti KOSKI ,  Ulla AIRAKSINEN ,  Katja VALIMAKI

IPC分类号： C12N9/86 ,  A61K9/48 ,  A61K9/00 ,  A61K31/545 ,  A61K31/43 ,  A61K45/06 ,  A61K38/50

摘要： The present invention relates to pharmaceuticals and modified beta-lactamases. Specifically, the invention relates to novel recombinant beta-lactamases and pharmaceutical compositions comprising the beta-lactamases.Also, the present invention relates to methods for modifying a beta-lactamase, producing the beta-lactamase and treating or preventing beta-lactam antibiotic induced adverse effects. Furthermore, the present invention relates to the beta-lactamase for use as a medicament and to the use of the beta-lactamase in the manufacture of a medicament for treating or preventing beta-lactam antibiotics induced adverse effects.Still further, the invention relates to a polynucleotide and a host cell comprising the polynucleotide.

公开(公告)号：US10046035B2

公开(公告)日：2018-08-14

申请号：US15641806

申请日：2017-07-05

申请人： SYNTHETIC BIOLOGICS, INC.

发明人： Michael Kaleko ,  Sheila Connelly ,  Vincent John Wacher

IPC分类号： A61K38/50 ,  A61K31/4164 ,  A61K35/74 ,  A61K35/741 ,  A61K38/14 ,  A61K9/16 ,  A61K9/50

摘要： This invention provides, in part, various compositions and methods for protecting the gastrointestinal microbiome from antibiotic disruption.

公开(公告)号：US09956292B2

公开(公告)日：2018-05-01

申请号：US14826115

申请日：2015-08-13

申请人： Cedars-Sinai Medical Center ,  Synthetic Biologics, Inc.

发明人： Mark Pimentel ,  Ruchi Mathur ,  Steve Kanzer ,  Vince Wacher

IPC分类号： A61K47/38 ,  A61K31/351 ,  A61K47/12 ,  A61K47/18 ,  A61K9/28 ,  A61K9/48 ,  A61K31/00

CPC分类号： A61K47/38 ,  A61K9/2054 ,  A61K9/2846 ,  A61K9/2886 ,  A61K9/4808 ,  A61K31/00 ,  A61K31/351 ,  A61K47/12 ,  A61K47/183

摘要： The present invention relates to, in part, methods and compositions for the treatment of methanogen-associated disorders such as, for example, Irritable Bowel Syndrome (IBS). Particularly, modified-release formulations comprising at least one antimethanogenic statin are provided which release the antimethanogenic statin in the intestines.

公开(公告)号：US20160362674A1

公开(公告)日：2016-12-15

申请号：US15245517

申请日：2016-08-24

申请人： Synthetic Biologics, Inc.

发明人： Michael Kaleko ,  Sheila Connelly

IPC分类号： C12N9/86

CPC分类号： C12N9/86 ,  A61K9/0053 ,  A61K31/546 ,  A61K38/00 ,  A61K38/50 ,  A61K45/06 ,  C12Y305/02006 ,  A61K2300/00

摘要： This invention relates to, in part, compositions of beta-lactamases and methods of using these enzymes in, for example, gastrointestinal tract (GI tract) disorders such as C. difficile infection (CDI).

公开(公告)号：US20160250304A1

公开(公告)日：2016-09-01

申请号：US15051187

申请日：2016-02-23

申请人： SYNTHETIC BIOLOGICS, INC.

发明人： Michael Kaleko ,  Sheila Connelly

IPC分类号： A61K38/50 ,  C12N9/86 ,  A61K9/00

CPC分类号： A61K38/50 ,  A61K9/0053 ,  A61K9/5026 ,  A61K9/5078 ,  A61K31/00 ,  A61K31/427 ,  A61K31/43 ,  A61K35/741 ,  A61K38/14 ,  C12N9/86 ,  C12Y305/02006 ,  Y02A50/473 ,  A61K2300/00

摘要： This invention relates, in part, to various compositions and methods for protecting the gastrointestinal microbiome from antibiotic disruption.

摘要翻译： 本发明部分涉及用于保护胃肠微生物组织免受抗生素破坏的各种组合物和方法。

公开(公告)号：US20160230160A1

公开(公告)日：2016-08-11

申请号：US15138767

申请日：2016-04-26

申请人： Synthetic Biologics, Inc.

发明人： Pertti Koski ,  Ulla Airaksinen ,  Katja Valimaki

IPC分类号： C12N9/86

CPC分类号： C12N9/86 ,  A61K9/0053 ,  A61K9/4891 ,  A61K31/43 ,  A61K31/545 ,  A61K38/00 ,  A61K38/50 ,  A61K45/06 ,  C12Y305/02006

摘要： The present invention relates to pharmaceuticals and modified beta-lactamases. Specifically, the invention relates to novel recombinant beta-lactamases and pharmaceutical compositions comprising the beta-lactamases. Also, the present invention relates to methods for modifying a beta-lactamase, producing the beta-lactamase and treating or preventing beta-lactam antibiotic induced adverse effects. Furthermore, the present invention relates to the beta-lactamase for use as a medicament and to the use of the beta-lactamase in the manufacture of a medicament for treating or preventing beta-lactam antibiotics induced adverse effects.Still further, the invention relates to a polynucleotide and a host cell comprising the polynucleotide.